A Sensitivity Scale for Targeting T Cells

Sep 5, 2023

A Sensitivity Scale for Targeting T Cells with Chimeric Antigen Receptors (CAR) and Bispecific T Cell Engagers (BiTE)

Friday, April 6, 2012 • 2:15-2:30 PM

Authors: Jennifer D. Stone*, David H. Aggen, Hans Schreiber, and David M. Kranz

Using a patients immune system to target cancer and maintain long-term surveillance is an attractive goal. Although T cells can respond potently to tumors, immune tolerance mechanisms often result in deletion or inactivation of those T cells expressing specific T cell receptors (TCRs) against effective target epitopes. To overcome this problem, two approaches using antibodies against cancer-associated epitopes have been designed to re-direct T cell activity. In one approach, the binding domain (scFv) of an anti-cancer antibody is linked to intracellular signaling domains, yielding a chimeric antigen receptor (CAR) that is expressed on ex vivo-activated T cells for adoptive therapy. In the second approach, the anti-cancer scFv is fused to another scFv that binds the TCR/CD3 complex, yielding an injectable product called a bispecific T cell engager (BiTE). Here, we directly compared the sensitivity of each strategy directed against a unique tumor epitope on the transmembrane glycoprotein OTS8. While both approaches showed efficient anti-tumor activities, CAR-targeted T cells were consistently more sensitive than BiTE-targeted T cells to low numbers of antigens per target cell. Using a panel of targets with varying levels of OTS8, we have constructed a sensitivity scale, providing a guide for applying these approaches under various conditions.